Cargando…
(68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making
OBJECTIVE: To evaluate the diagnostic performance of [(68)Ga]Ga-PSMA(HBED-CC) conjugate 11 positron emission tomography (PSMA-PET) in the early detection of metastases in patients with biochemical recurrence (BCR) after radical prostatectomy (RP) for clinically non-metastatic prostate cancer, to com...
Autores principales: | Grubmüller, B., Baltzer, P., D’Andrea, D., Korn, S., Haug, A. R., Hacker, M., Grubmüller, K. H., Goldner, G. M., Wadsak, W., Pfaff, S., Babich, J., Seitz, C., Fajkovic, H., Susani, M., Mazal, P., Kramer, G., Shariat, S. F., Hartenbach, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745568/ https://www.ncbi.nlm.nih.gov/pubmed/29075832 http://dx.doi.org/10.1007/s00259-017-3858-2 |
Ejemplares similares
-
Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018) -
Prospective evaluation of the performance of [(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy
por: Abufaraj, Mohammad, et al.
Publicado: (2019) -
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [(68)Ga]Ga-PSMA-11 PET/MRI
por: Papp, L., et al.
Publicado: (2020) -
Direct Patlak Reconstruction of [(68)Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study
por: Rasul, Sazan, et al.
Publicado: (2023) -
Feasibility and Optimal Time Point of [(68)Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery
por: Huebner, Nicolai, et al.
Publicado: (2022)